This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
by Aparajita Dutta
Eli Lilly's $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven pharma space.
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
by Aparajita Dutta
Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
by Aparajita Dutta
Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
by Aparajita Dutta
Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.
The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
by Aparajita Dutta
FDA approval of NVO's oral Wegovy could reshape obesity care and lift healthcare ETFs, offering investors diversified exposure to the GLP-1 boom.
Pharma's $370B Bet on America: The ETF Plays for 2026
by Aparajita Dutta
Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.
Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
by Aparajita Dutta
Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.